Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, shares her perspectives on key ongoing research topics in lung cancer. To begin with, it is important to accelerate the development of biomarkers that will help identify the most appropriate drug for newly diagnosed patients with non-small cell lung cancer (NSCLC), as well as biomarkers of drug resistance for patients who progress on anti-PD-1 therapy. Moreover, novel promising immunotherapies such as antibody-drug conjugates and bispecific antibodies are currently being examined for NSCLC and small cell lung cancer (SCLC). Dr Johnson also comments on the recent approval of sotorasib for patients with KRAS G12C-mutated NSCLC and mentions ongoing research focusing on improving the efficacy of this KRAS G12C inhibitor, as well as research on new targeted therapies and immunotherapies for patients with NSCLC with other KRAS mutations. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.